Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease.
Alzheimer’s disease
Care partner
Caregiver
Clinical outcome assessment
Clinically meaningful
Outcomes
Patient
Value
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
20
11
2022
accepted:
23
01
2023
medline:
16
2
2023
pubmed:
16
2
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
Insight into the relationship between concepts that matter to the people affected by Alzheimer's disease (AD) and the clinical outcome assessments (COAs) commonly used in AD clinical studies is limited. Phases 1 and 2 of the What Matters Most (WMM) study series identified and quantitatively confirmed 42 treatment-related outcomes that are important to people affected by AD. We compared WMM concepts rated as "very important" or higher to items included in COAs used commonly in AD studies. Twenty COAs designed to assess signs, symptoms, and impacts across the spectrum of AD were selected for review. Among these 20 COAs, only 5 reflected 12 or more WMM concepts [Integrated Alzheimer's Disease Rating Scale (iADRS), Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL), Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory-Mild Cognitive Impairment (ADCS-ADL-MCI), Alzheimer's Disease Composite Scores (ADCOMS), and Clinical Dementia Rating; Clinical Dementia Rating-Sum of Boxes (CDR/CDR-SB)]. Multiple symptoms and impacts of AD identified as important and meaningful in the WMM studies map only indirectly at best to 7 of the 20 most widely used COAs. While many frequently used COAs in AD capture some concepts identified as important to AD populations and their care partners, overlap between any single measure and the concepts that matter to people affected by AD is limited. The highest singly matched COA reflects fewer than half (45%) of WMM concepts. Use of multiple COAs expands coverage of meaningful concepts. Future research should explore the content validity of AD COAs planned for AD trials based on further confirmation of the ecological validity of the WMM items. This research should inform development and use of core outcome sets that capture WMM items and selection or development of new companion tools to fully demonstrate clinically meaningful outcomes spanning WMM.
Identifiants
pubmed: 36790638
doi: 10.1007/s40120-023-00443-2
pii: 10.1007/s40120-023-00443-2
pmc: PMC10043075
doi:
Types de publication
Journal Article
Langues
eng
Pagination
571-595Informations de copyright
© 2023. The Author(s).
Références
DiBenedetti D, Slota C, Wronski SL, Vradenburg G, Comer M, Callahan LF, et al. Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. 2020;12(1):90.
doi: 10.1186/s13195-020-00659-6
pubmed: 32731886
pmcid: 7393916
Hauber et al. Assessing what matters to people affected by alzheimer’s disease: a quantitative analysis (forthcoming).
Jutten RJ, Papp KV, Hendrix S, Ellison N, Langbaum JB, Donohue MC, et al. Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. Alzheimers Dement. 2022. https://doi.org/10.1002/alz.12773 .
doi: 10.1002/alz.12773
pubmed: 36086926
US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf . Accessed 31 Mar 2022.
US Food and Drug Administration. Patient-focused drug development guidance public workshop: Methods to identify what is important to patients & select, develop or modify fit for purpose clinical outcomes assessments. 2018. https://www.fda.gov/media/116281/download . Accessed 31 Mar 2022.
US Food and Drug Administration. Patient-focused drug development guidance series for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making. https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical . Accessed 31 Mar 2022.
Abushakra S, Sadowsky CH, Porsteinsson AP, Gauthier S, Vellas B, Power A, et al. Clinical effects of tramiprosate in APOE4 homozygotes with mild to moderate Alzheimer’s disease (ad) are sustained over 130 weeks: Results of a phase 3 extension study. Alzheimers Dement. 2017;13(7):P256.
Bago Rozankovic P, Badzak J. Impact of donepezil and memantine on behavioral and psychological symptoms in patients with Alzheimer’s disease. Eur J Neurol. 2015;22:579.
Bowen RL, Perry G, Xiong C, Smith MA, Atwood CS. A clinical study of lupron depot in the treatment of women with Alzheimer’s disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis. 2015;44(2):549–60.
doi: 10.3233/JAD-141626
pubmed: 25310993
Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimers Dis. 2015;44(3):897–906.
doi: 10.3233/JAD-141791
pubmed: 25374101
Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Sanon M. Level of care dependency and functional status among patients with Alzheimer’s disease and agitation/aggression symptoms. Am J Geriatr Psychiatry. 2019;27(3):S151–2.
doi: 10.1016/j.jagp.2019.01.106
Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, et al. Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers: a pilot clinical trial. J Alzheimers Dis. 2017;57(4):1325–34.
doi: 10.3233/JAD-161256
pubmed: 28372335
pmcid: 5409050
Cumbo E, Cumbo S, Torregrossa S, Migliore D. Effects of vortioxetine on cognitive functions in patients with Alzheimer’s disease and depressive symptoms: Interim results of an observational study. J Prev Alzheimer’s Dis. 2018;5(1):S58–9.
Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, et al. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889–97.
doi: 10.1212/WNL.0000000000005550
pubmed: 29695589
pmcid: 5962917
Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–54.
doi: 10.1001/jama.2015.10214
pubmed: 26393847
Fullerton T, Binneman B, David W, Delnomdedieu M, Kupiec J, Lockwood P, et al. A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil. Alzheimers Res Ther. 2018;10(1):38.
doi: 10.1186/s13195-018-0368-9
pubmed: 29622037
pmcid: 5887246
Gauthier S, Rountree S, Finn B, LaPlante B, Weber E, Oltersdorf T. Effects of the acetylcholine release agent ST101 with donepezil in Alzheimer’s disease: a randomized phase 2 study. J Alzheimers Dis. 2015;48(2):473–81.
doi: 10.3233/JAD-150414
pubmed: 26402011
Henderson VW, Ala T, Sainani KL, Bernstein AL, Stephenson BS, Rosen AC, et al. Raloxifene for women with Alzheimer disease: a randomized controlled pilot trial. Neurology. 2015;85(22):1937–44.
doi: 10.1212/WNL.0000000000002171
pubmed: 26537053
pmcid: 4664126
Herrmann N, O’Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, et al. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. J Am Med Dir Assoc. 2016;17(2):142–7.
doi: 10.1016/j.jamda.2015.08.019
pubmed: 26482056
Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, et al. IVIG treatment of mild cognitive impairment due to Alzheimer’s disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Neurosurg Psychiatry. 2017;88(2):106–12.
doi: 10.1136/jnnp-2015-311486
pubmed: 26420886
Lanctôt KL, Ruthirakuhan M, O’Regan JN, Eryavec G, Williams E, Black SE, et al. Cholinesterase inhibitor discontinuation in institutionalized persons with moderate to severe AD: Results of a double-blind, placebo controlled trial. Am J Geriatr Psychiatry. 2015;23(3):S172–3.
doi: 10.1016/j.jagp.2014.12.181
Nosheny RL, Flennkiken D, Insel PS, Finley S, Mackin S, Camacho M, et al. Internet-based recruitment of subjects for prodromal and secondary prevention Alzheimer’s disease trials using the brain health registry. Alzheimers Dement. 2015;11(7):P156.
Olsson T, Alexander R, Budd Haeberlein S, Hannesdottir K, Andrews T, Curry L, et al. Use of a telephone interview methodology to identify subjects with cognitive impairment among those reporting subjective memory complaints. Neurodegener Dis. 2015;15:836.
Salloway SP, Sperling R, Fox NC, Sabbagh MN, Honig LS, Porsteinsson AP, et al. Long-Term follow up of patients with mild-to-moderate Alzheimer’s disease treated with bapineuzumab in a phase III, open-label, extension study. J Alzheimers Dis. 2018;64(3):689–707.
doi: 10.3233/JAD-171157
pubmed: 29914022
Steinberg MI, Leoutsakos JMS. The association between general medical health and course of cognition, function, and neuropsychiatric symptoms in the cache county dementia progression study. Alzheimers Dement. 2015;11(7):P261.
Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18.
doi: 10.1186/s13195-016-0189-7
pubmed: 27176461
pmcid: 4866415
Wharton W, Goldstein FC, Zhao L, Steenland K, Levey AI, Hajjar I. Modulation of renin-angiotensin system may slow conversion from mild cognitive impairment to Alzheimer’s disease. J Am Geriatr Soc. 2015;63(9):1749–56.
doi: 10.1111/jgs.13627
pubmed: 26389987
pmcid: 4743657
Yamamoto E, Mourany L, Colleran R, Whitman C, Tousi B. Utility of montreal cognitive assessment in differentiating dementia with Lewy bodies from Alzheimer’s dementia. Am J Alzheimers Dis Other Demen. 2017;32(8):468–71.
doi: 10.1177/1533317517725811
pubmed: 28871793
Assunção SS, Sperling RA, Ritchie C, Kerwin DR, Aisen PS, Lansdall C, Atri A, Cummings J. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):54.
doi: 10.1186/s13195-022-00984-y
pubmed: 35440022
pmcid: 9017027
Rentz DM, Wessels AM, Annapragada AV, Berger AK, Edgar CJ, Gold M, Miller DS, Randolph C, Ryan JM, Wunderlich G, Zoschg MC, Trépel D, Knopman DS, Staffaroni AM, Bain LJ, Carrillo MC, Weber CJ. Building clinically relevant outcomes across the Alzheimer’s disease spectrum. Alzheimers Dement (N Y). 2021;7(1): e12181.
pubmed: 34195350
Edgar CJ, Vradenburg G, Hassenstab J. The 2018 revised FDA guidance for early Alzheimer’s disease: establishing the meaningfulness of treatment effects. J Prev Alzheimers Dis. 2019;6(4):223–7.
pubmed: 31686092